Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Current controversies in the formation and treatment of alloantibodies to factor VIII in congenital hemophilia A.

Kruse-Jarres R.

Hematology Am Soc Hematol Educ Program. 2011;2011:407-12. doi: 10.1182/asheducation-2011.1.407. Review.

PMID:
22160066
2.

Inhibitor antibodies to factor VIII and factor IX: management.

Lusher JM.

Semin Thromb Hemost. 2000;26(2):179-88. Review.

PMID:
10919411
3.

New protocol for immune tolerance induction in acquired hemophilia.

Nemes L, Pitlik E.

Haematologica. 2000 Oct;85(10 Suppl):64-8.

PMID:
11187874
4.

[Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia].

Ishiguro A.

Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(6):476-84. Review. Japanese.

5.

Immune tolerance induction in patients with hemophilia A.

Astermark J.

Thromb Res. 2011 Jan;127 Suppl 1:S6-9. doi: 10.1016/j.thromres.2010.10.006. Epub 2010 Nov 5.

PMID:
21056905
7.

Role of von Willebrand factor in immune tolerance induction.

Ettingshausen CE, Kreuz W.

Blood Coagul Fibrinolysis. 2005 Apr;16 Suppl 1:S27-31. Review.

PMID:
15849524
8.

The role of VWF for the success of immune tolerance induction.

Kreuz W.

Thromb Res. 2008;122 Suppl 2:S7-S12. doi: 10.1016/S0049-3848(08)70003-3. Review.

PMID:
18549910
9.

Factor VIII inhibitors in patients with hemophilia A: epidemiology of inhibitor development and induction of immune tolerance for factor VIII.

Kreuz W, Becker S, Lenz E, Martinez-Saguer I, Escuriola-Ettingshausen C, Funk M, Ehrenforth S, Auerswald G, Kornhuber B.

Semin Thromb Hemost. 1995;21(4):382-9.

PMID:
8747701
10.

Immune tolerance induction for the eradication of inhibitors in patients with hemophilia A.

Kruse-Jarres R, Barnett B, Leissinger C.

Expert Opin Biol Ther. 2008 Dec;8(12):1885-96. doi: 10.1517/14712590802515537 . Review.

PMID:
18990076
11.

Forum on: the role of recombinant factor VIII in children with severe haemophilia A.

Franchini M, Coppola A, Molinari AC, Santoro C, Schinco P, Speciale V, Tagliaferri A.

Haemophilia. 2009 Mar;15(2):578-86. doi: 10.1111/j.1365-2516.2008.01975.x. Epub 2009 Feb 1.

PMID:
19187188
12.

Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.

Lin PC, Liao YM, Tsai SP, Chang TT.

Pediatr Blood Cancer. 2011 Dec 1;57(6):1029-33. doi: 10.1002/pbc.23291. Epub 2011 Jul 26.

PMID:
21793191
13.

Immune tolerance induction for patients with severe hemophilia A: a critical literature review.

Franchini M, Lippi G.

J Thromb Thrombolysis. 2011 Nov;32(4):439-47. doi: 10.1007/s11239-011-0624-3. Review.

PMID:
21818664
14.
15.

The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.

Auerswald G, Spranger T, Brackmann HH.

Haematologica. 2003 Jun;88(6):EREP05. Review.

PMID:
12826531
16.

The immune tolerance induction (ITI) dose debate: does the International ITI Study provide a clearer picture?

Ettingshausen CE, Kreuz W.

Haemophilia. 2013 Jan;19 Suppl 1:12-7. doi: 10.1111/hae.12051. Review.

PMID:
23278995
17.

Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives.

Tellier Z, André MH, Polack B.

Clin Rev Allergy Immunol. 2009 Oct;37(2):125-34. doi: 10.1007/s12016-009-8115-4. Review.

PMID:
19184560
18.

The role of immunomodulation in the management of factor VIII inhibitors.

Lillicrap D.

Hematology Am Soc Hematol Educ Program. 2006:421-5. Review.

PMID:
17124093
19.

Epidemiology of inhibitors and current treatment strategies.

Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T; GTH PUP Study Group.

Haematologica. 2003 Jun;88(6):EREP04. Review.

PMID:
12826530
20.

Inhibitors in haemophilia A: current management and open issues.

Haya S, Moret A, Cid AR, Cortina V, Casaña P, Cabrera N, Aznar JA.

Haemophilia. 2007 Dec;13 Suppl 5:52-60. doi: 10.1111/j.1365-2516.2007.01574.x. Review.

PMID:
18078398
Items per page

Supplemental Content

Write to the Help Desk